Media stories about Neos Therapeutics (NASDAQ:NEOS) have trended somewhat positive recently, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Neos Therapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.0151711472018 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- Cantor Fitzgerald Reaffirms Their Buy Rating on Neos Therapeutics – Analyst Ratings (analystratings.com)
- A Look Under the Hood at Profitability For These Stocks: PICO Holdings, Inc. (NasdaqGS:PICO), Neos Therapeutics … – Aldan Post (aldanpost.com)
- Neos Therapeutics (NEOS) Upgraded to Hold by Zacks Investment Research (americanbankingnews.com)
- Neos Therapeutics Inc (NASDAQ:NEOS): Time For A Financial Health Check (finance.yahoo.com)
- Cantor Fitzgerald Analysts Give Neos Therapeutics (NEOS) a $20.00 Price Target (americanbankingnews.com)
NEOS has been the topic of several research analyst reports. BidaskClub raised shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 27th. Zacks Investment Research raised shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday. Cantor Fitzgerald set a $20.00 price target on shares of Neos Therapeutics and gave the company a “buy” rating in a research note on Monday, January 8th. BMO Capital Markets cut shares of Neos Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 31st. Finally, Wells Fargo set a $14.00 price objective on shares of Neos Therapeutics and gave the company a “buy” rating in a report on Saturday, March 17th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. Neos Therapeutics currently has an average rating of “Hold” and a consensus target price of $15.00.
Neos Therapeutics (NASDAQ:NEOS) last announced its quarterly earnings data on Thursday, March 15th. The company reported ($0.49) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.61) by $0.12. Neos Therapeutics had a negative net margin of 264.80% and a negative return on equity of 437.92%. The business had revenue of $7.79 million for the quarter, compared to analyst estimates of $9.30 million. equities research analysts expect that Neos Therapeutics will post -1.53 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Neos Therapeutics (NEOS) Earning Somewhat Positive News Coverage, Analysis Shows” was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3296650/neos-therapeutics-neos-earning-somewhat-positive-news-coverage-analysis-shows.html.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.